JP2025508820A5 - - Google Patents

Info

Publication number
JP2025508820A5
JP2025508820A5 JP2024550131A JP2024550131A JP2025508820A5 JP 2025508820 A5 JP2025508820 A5 JP 2025508820A5 JP 2024550131 A JP2024550131 A JP 2024550131A JP 2024550131 A JP2024550131 A JP 2024550131A JP 2025508820 A5 JP2025508820 A5 JP 2025508820A5
Authority
JP
Japan
Prior art keywords
acid
gglu
valine
aib
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508820A (ja
Filing date
Publication date
Priority claimed from EP22158188.7A external-priority patent/EP4234574A1/en
Application filed filed Critical
Publication of JP2025508820A publication Critical patent/JP2025508820A/ja
Publication of JP2025508820A5 publication Critical patent/JP2025508820A5/ja
Pending legal-status Critical Current

Links

JP2024550131A 2022-02-23 2023-02-21 Crf2受容体アゴニスト及び治療法におけるそれらの使用 Pending JP2025508820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
EP22158188.7 2022-02-23
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (2)

Publication Number Publication Date
JP2025508820A JP2025508820A (ja) 2025-04-10
JP2025508820A5 true JP2025508820A5 (cg-RX-API-DMAC10.html) 2025-12-23

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550131A Pending JP2025508820A (ja) 2022-02-23 2023-02-21 Crf2受容体アゴニスト及び治療法におけるそれらの使用

Country Status (15)

Country Link
US (1) US20260001928A1 (cg-RX-API-DMAC10.html)
EP (3) EP4234574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508820A (cg-RX-API-DMAC10.html)
KR (1) KR20240153565A (cg-RX-API-DMAC10.html)
CN (1) CN118843638A (cg-RX-API-DMAC10.html)
AU (1) AU2023224327A1 (cg-RX-API-DMAC10.html)
CA (1) CA3247142A1 (cg-RX-API-DMAC10.html)
ES (1) ES3063881T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20260115T1 (cg-RX-API-DMAC10.html)
IL (1) IL314055A (cg-RX-API-DMAC10.html)
IS (1) IS050770A (cg-RX-API-DMAC10.html)
MX (1) MX2024010296A (cg-RX-API-DMAC10.html)
PL (1) PL4482578T3 (cg-RX-API-DMAC10.html)
WO (1) WO2023161229A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202406196B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260089954A (ko) * 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US12679878B2 (en) * 2020-08-19 2026-07-14 Sanofi CRF2 receptor agonists and their use in therapy

Similar Documents

Publication Publication Date Title
HRP20240906T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
JP2023541798A5 (cg-RX-API-DMAC10.html)
US9221871B2 (en) Methods for preparing internally constrained peptides and peptidomimetics
PE20231841A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CN104583232B (zh) 展现gip受体活性的胰高血糖素类似物
JP2012512901A5 (cg-RX-API-DMAC10.html)
HUE035378T2 (en) Compstatin with peptide framework and C-terminal modifications
WO2020190757A1 (en) Improved processes for the preparation of semaglutide
CA2931694C (en) Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
JP2016519106A5 (cg-RX-API-DMAC10.html)
US9850285B2 (en) Process for preparing eptifibatide
DE602008004897D1 (de) Verbindungen zur diagnose von mit der vcam-expression assoziierten krankheiten
RU2726414C2 (ru) Новые способы получения барусибана и его промежуточных соединений
RU2024126937A (ru) Агонисты рецепторов crf2 и их применение в терапии
JP2633369B2 (ja) ペプチド
US5580855A (en) Peptides
WO2017149098A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
JP2017512760A (ja) 環状アペリン類似体
JPWO2023190812A5 (cg-RX-API-DMAC10.html)
JP2020142994A (ja) 血管機能の検出方法、高血圧症の進行段階を判定する方法、高血圧症の進行段階を判定するためのキット及び高血圧症の治療効果の予測方法
WO2025043696A1 (zh) 抗病毒多肽类似物
JPWO2025142861A5 (cg-RX-API-DMAC10.html)
AU629826C (en) Peptides
WO1992019644A1 (fr) Peptide vasodilatateur